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Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149S1442-tailed t-test P ¼ .74, Figure 1A). Results depend on the type
of transplant received, however, as MUD transplants showed
a differential expression in serum uric acid levels between
the two groups (2.64mg/dl for aGVHD+ vs. 2.18 for aGVHD-,
P ¼ .047, Figure 1B), while MRD transplants did not show
a difference (2.97mg/dl for aGVHD+ vs. 2.98 for aGVHD-, P ¼
.95, Figure 1C). Patients given rasburicase had a lower serum
uric acid level compared to the control arm (0.213mg/dl vs.
3.04 for d-7 to -2; 1.20mg/dl vs. 2.85 over all days, P < .0001)
as well as signiﬁcantly less aGVHD (rasburicase: 22% vs.
control: 48%, Fisher's exact test, P ¼ .033). Lower serum uric
acid level at the time of transplantation appears to be
protective against the development of aGVHD among
patients receiving matched unrelated donor transplants.
Rasburicase, when administered during the conditioning,
signiﬁcantly lowers the serum uric acid level and appears to
decrease aGVHD.
Figure 1. Mean uric acid levels from day-7 to day+6 between control patients
who developed aGVHD2+ (Red) vs. no aGVHD2+ (Blue).HEMATOPOIESIS/MESENCHYMAL CELLS ORAL
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Introduction: Despite improvements in the last decade in
the ﬁeld of HSCT, acute graft versus host disease (aGVHD)
remains a life-threatening complication of HSCT. In partic-
ular, the outcome of patients with severe steroid-resistant
aGVHD is very poor. Therefore, it remains important to
search for new therapeutic strategies.
Objective: The feasibility of the generation ofMSCs expanded
with platelet lysate (PL) was tested as well as the feasibility
and safety of the application in patients with steroid-refrac-
tory aGVHD. Immunological changes after infusion of MSC
were characterized, in vitro. However, truly active mecha-
nisms in human are poorly understood as well as whether
infusion of MSC selectively impairs GVHD-inducing immune
cells or also anti-virus and anti-leukemia reactive T-cells.Phenotypical and functional changes in immunological cell
types and cytokine levels were investigated.
Method: In an open-label, non-randomized prospective
phase I/II study MSCs from the bone marrow of healthy
volunteers, expanded with PL. Patients with steroid-refrac-
tory aGVHD grade II-IV were treated with PL-MSC. 50
patients were included and received up to 4 infusions.
Response rate, transplantation-related deaths, and other
adverse events were assessed for up to 12 months after
inclusion. In addition, a comprehensive phenotypical and
functional analysis was performed with PBMCs and serum
isolated from all patients before, during, and after infusion of
MSC.
Results: Between 2009-2012, 50 patients were included, 2
dropped out, 5 are so far incompletely documented. Thus 43
were available for analysis, 6 children and 37 adults. Median
age was 51,5 yr (1.3-65.9). Organs involved in aGVHD were
skin (56%), gi-tract (86%) and liver (33%). Overall grade was II
26%, III 65%, and IV 7%. Mean number of infusion were 3 (1-
4). No severe side effects were observed. Median follow-up
was 4 months (0.4-12). Complete overall response was
observed in 56% patients after a median of 53 days (3-116).
The overall survival was signiﬁcantly better in responders
when compared to non-responders (p <0.001). Immuno-
logical monitoring suggests that anti-viral and anti-leukemia
reactive T-cells are well preserved in all patients who
responded to MSC treatment. In addition, we identiﬁed
biomarkers which associate even 2 weeks after MSC infusion
with complete resolution of GVHD.
Conclusion: Generation and infusion of PL-MSCs in steroid-
resistant aGVHD grade II- IV is feasible, safe and is effective.
In addition, also patients who initially responded to PL-MSCs
but develop later a relapse of aGVHD during tapering or
cessation of immunosuppressive drugs become again sensi-
tive to the treatment with steroids. Infusion of MSC did not
impair anti-virus and anti-leukemia reactive T-cells. Identi-
ﬁed biomarkers predict very early a usually late clinical
resolution of GVHD, thus might be useful.HISTOCOMPATIBILITY/ALTERNATIVE STEM CELL SOURCES
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Background: Retrospective studies suggest that double-unit
cord blood (CB) grafts may improve engraftment and protect
against relapse as compared with that observed after single-
unit CB transplantation (CBT). However, whether the
Abstracts / Biol Blood Marrow Transplant 19 (2013) S129eS149 S145promising disease-free survival (DFS) reported in single
center series can be replicated in a multi-center setting has
not been established.
Methods:We performed a prospective multi-center study of
myeloablative double-unit CBT in adults. Eligible patients
were 22-50 years and had acute leukemia in morphologic
remission or MDS (<10% bonemarrow blasts at work-up). CB
grafts were 4-6/6 HLA-A,B antigen, -DRB1 allele matched to
the recipient with a cryopreserved TNC  1.5 x 107/kg/unit
and units were 3-6/6 HLA-matched to each other. Condi-
tioning consisted of cyclophosphamide 120 mg/kg, ﬂudar-
abine 75 mg/m2, and total body irradiation 1320 cGy with
cyclosporine-A and mycophenolate mofetil 1 gram every 12
hours as GVHD prophylaxis.
Results: Fifty-six patients [median 35 years (range 18-49),
median weight 78 kg (range 53-127), and 33 (59%) CMV
seropositive] were transplanted at 10 centers between 2007
and 2011. Thirty patients had AML (13 CR1, 17 CR2), 19 had
ALL (11 CR1, 8 CR2), 4 had acute biphenotypic or undiffer-
entiated leukemia (3 CR1,1 CR2), and 3 hadMDS. Themedian
infused TNC doses were 2.9 x 107/kg and 2.1 x 107/kg for the
larger and smaller units, respectively, and 4 (3%) units were
6/6, 40 (36%) 5/6, and 68 (61%) 4/6 HLA-matched to the
recipient. The cumulative incidence of sustained donor
neutrophil engraftment was 90% (95%CI: 82-96) at day 42
and 91% (95%CI: 82-97) at day 100 with a median time to
neutrophil recovery of 22 days (range 13-94). Seventy
percent (95%CI: 58-82) of patients had platelet recovery at
day 180. The incidences of grade II-IV and III-IV acute graft-
versus-host disease (GVHD) by day 100 were 66% (95%CI: 53-
78) and 39% (95%CI: 27-52), respectively, and 21% (95%CI: 12-
33) had chronic GVHD by 1-year. Day 180 transplant-related
mortality (TRM) was 32% (95%CI: 21-45), and the 2-year
relapse incidence was 10% (95%CI: 3-20). With a median
follow-up of survivors of 24 months (range 11-26), 1-year
and 2-year Kaplan-Meier estimates of DFS are 57% (95%CI:
44-70) and 50% (95%CI: 37-64), respectively. Of 26 patients
who have died, 21 died of TRM which was most commonly
due to GVHD (n ¼ 9) followed by graft failure (n ¼ 4),
infection (n ¼ 4), and organ failure (n ¼ 4).
Conclusions: Double-unit CBT is a viable alternative treat-
ment for high-risk acute leukemia and MDS, especially in
those lacking a matched unrelated donor. However, our
results highlight the need for further improvement in this
therapy. The major challenges for patients were delayed or
failed engraftment, infection, organ toxicity, and GVHD,
whereas the relapse incidence was low. Strategies to further
ameliorate the TRM after myeloablative double-unit CBT are
needed.Table
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recipient at HLA-A,B antigens & -DRB1 alleles with up to 2
mismatches permitted, signiﬁcant associations between
intermediate resolution HLA-C matching, & also HLA-
A,B,DRB1 allele matching, & CB transplantation (CBT)
outcomes have recently been reported. This suggests that CB
donor-recipient match criteria should be upgraded to 6 HLA-
alleles or higher. However, how to clinically implement
higher resolution HLA-matching & its affect upon CB unit
selection are unknown.
Methods: We analyzed the HLA-match grade of 96 double-
unit CB grafts (units 1a & 1b) & the 1-2 back-up units chosen
for each transplant at various match grades. 362 CB units
were selected for 95 patients (1 patient was transplanted
twice) who underwent CBT from 1/2009-6/2012 for hema-
tologic malignancies. Units were selected based on cry-
opreserved TNC dose ( 1.5, later increased to  2.0 x 107/
kg), donor-recipient 4-6/6 HLA-A,B antigen, -DRB1 allele
match & CB bank. Unit-unit match was not considered. High-
resolution typing was obtained prospectively but usually did
not inﬂuence unit selection.
Results: The median age was 41 years (range 1-69) & the
median weight was 65 kgs (range 10-125). The median TNC/
kg x 107 of units 1a & 1b (n ¼ 192) was 2.89 (range 1.53-
17.78), & their median donor-recipient HLA-match was 4/6
(range 1-6/6), 5/8 (range 2-8/8), & 6/10 (range 2-9/10) at 6, 8
& 10 HLA-alleles, respectively. The median (range) of 6/6
HLA-A,B antigen,-DRB1 allele matched units (n ¼ 9) was 6/6
(3-6/6), 7/8 (5-8/8) & 9/10 (7-9/10) at 6, 8, & 10 allele reso-
lution, respectively. However, 5/6 HLA-A,B antigen, -DRB1
allele matched units (n ¼ 90) were a median (range) of 5/6
(2-5/6), 6/8 (3-7/8) & 7/10 (3-9/10) at allele resolution.
Moreover, 4/6 HLA-A,B antigen, -DRB1 allele matched units
(n ¼ 93) were a median (range) of 3/6 (1-4/6), 4/8 (2-6/8) &
5/10 (2-8/10) at allele resolution. We then evaluated how
often the use of higher resolution HLA-match criteria would
change graft selection to substitute one or both back-up units
over units 1a &/or 1b, & the effect on the graft TNC dose
(Table). If a TNC/kg  2.0 x 107 & a better HLA-match were
required, unit selection would change in 38/96 (40%) of
transplants for 10 allele HLA-match. The effect on TNC was
minimal ( 12% reduction in the total graft TNC dose).
Conclusions: Units currently chosen based on HLA-A, B
antigen, -DRB1 allele match have a very high degree of
mismatch at higher resolution. Adoption of higher match
grade criteria will frequently change the selection of the
“optimal” graft. While the new lower limit of acceptable
HLA-match & how to “trade off” higher resolution match
against TNC dose are unknown, our data suggest that higher
resolution HLA-match is frequently possible without signif-
icant compromise in graft dose.
